# EX02 CAR-T Cells for Relapsed and Refractory Acute Myeloid Leukemia

> **NCT06642025** · EARLY_PHASE1 · RECRUITING · sponsor: **Zhimin Zhai** · enrollment: 9 (estimated)

## Conditions studied

- Acute Myeloid Leukemia (AML)
- CAR-T

## Interventions

- **BIOLOGICAL:** CAR-T Cell Injection

## Key facts

- **NCT ID:** NCT06642025
- **Lead sponsor:** Zhimin Zhai
- **Sponsor class:** OTHER
- **Phase:** EARLY_PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-09-01
- **Primary completion:** 2026-08-01
- **Final completion:** 2029-09-01
- **Target enrollment:** 9 (ESTIMATED)
- **Last updated:** 2024-10-15

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06642025

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06642025, "EX02 CAR-T Cells for Relapsed and Refractory Acute Myeloid Leukemia". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06642025. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*